Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Long-Term Deferred Tax: 2016-2019

Historic Long-Term Deferred Tax for Niagen Bioscience (NAGE) over the last 4 years, with Dec 2019 value amounting to $30.5 million.

  • Niagen Bioscience's Long-Term Deferred Tax rose 38.34% to $30.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was $30.5 million, marking a year-over-year increase of 38.34%. This contributed to the annual value of $30.5 million for FY2019, which is 38.34% up from last year.
  • Niagen Bioscience's Long-Term Deferred Tax amounted to $30.5 million in FY2019, which was up 38.34% from $22.1 million recorded in FY2018.
  • In the past 5 years, Niagen Bioscience's Long-Term Deferred Tax registered a high of $30.5 million during FY2019, and its lowest value of $13.0 million during FY2017.
  • For the 3-year period, Niagen Bioscience's Long-Term Deferred Tax averaged around $21.9 million, with its median value being $22.1 million (2018).
  • In the last 5 years, Niagen Bioscience's Long-Term Deferred Tax fell by 18.09% in 2017 and then skyrocketed by 69.14% in 2018.
  • Niagen Bioscience's Long-Term Deferred Tax (Yearly) stood at $15.5 million in 2016, then rose by 3.01% to $15.9 million in 2016, then fell by 18.09% to $13.0 million in 2017, then surged by 69.14% to $22.1 million in 2018, then soared by 38.34% to $30.5 million in 2019.